Theranexus (EPA:ALTHX)

BRIEF

published on 01/20/2026 at 18:05, 7 months 23 days ago

THX Pharma Reveals 2026 Financial Schedule

Financial Calendar Neurological Diseases Market Communication 2026 Announcements THX Pharma
PRESS RELEASE

published on 01/20/2026 at 18:00, 7 months 23 days ago

THX Pharma Announces its 2026 Financial Calendar
THX Pharma (Theranexus) announces financial communication agenda for 2026, focusing on rare neurological diseases treatments. Company listed on Euronext Growth Paris

Euronext Growth Paris Financial Communication Theranexus Neurological Diseases THX Pharma
BRIEF

published on 01/08/2026 at 18:05, 8 months 4 days ago

Publication of the letter to shareholders by Theranexus

Shareholders Neuroscience Rare Diseases Theranexus Drugs
BRIEF

published on 01/08/2026 at 18:05, 8 months 4 days ago

THX Pharma Releases Shareholder Letter

Drug Development Biopharmaceutical Shareholder Communication Neurological Diseases THX Pharma
PRESS RELEASE

published on 01/08/2026 at 18:00, 8 months 4 days ago

THX Pharma announces the publication of its letter to shareholders
THX Pharma (Theranexus) announces the publication of its letter to shareholders, highlighting treatments for rare neurological diseases and upcoming drug commercialization. Forward-looking statements included

Forward-looking Statements Theranexus Neurological Diseases THX Pharma Drug Commercialization
BRIEF

published on 01/07/2026 at 08:05, 8 months 6 days ago

THX Pharma appoints Julien Veys as Deputy General Manager

Business Strategy Appointment THX Pharma Julien Veys Neurological Medications
BRIEF

published on 01/07/2026 at 08:05, 8 months 6 days ago

THX Pharma Names Julien Veys as Deputy CEO

Rare Neurological Diseases THX Pharma Julien Veys Appointment Theranexus Strategy Pharmaceutical Commercialization
PRESS RELEASE

published on 01/07/2026 at 08:00, 8 months 6 days ago

THX Pharma Announces the Appointment of Julien Veys as Deputy Chief Executive Officer
THX Pharma appoints Julien Veys as Deputy CEO to drive new strategy focusing on regulatory approval and commercialization of medicines for rare neurological diseases

Regulatory Approval Deputy CEO Neurological Diseases THX Pharma Julien Veys
BRIEF

published on 11/13/2025 at 08:05, 10 months ago

THX Pharma successfully completes its €7.8 million capital increase

Investors Capital Increase New Actions Neurological Diseases THX Pharma
PRESS RELEASE

published on 11/13/2025 at 08:00, 10 months ago

THX Pharma announces the strong success of its approximately EUR 8 million capital increase to support its continued development and strengthen its financial structure
THX Pharma successfully raises €7.8 million through capital increase, issuing 4,356,804 new shares at €1.80 each. Existing shareholders show strong support. Subscription period ran from Oct 29 to Nov 7, 2025, for the fully funded roadmap

Shareholders Capital Increase New Shares Subscription Period THX Pharma

Published on 09/12/2026 at 02:35, 1 day 8 hours ago

Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 11 hours ago

Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 1 day 12 hours ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 1 day 13 hours ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 17 hours ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE

Published on 09/12/2026 at 17:50, 17 hours 3 minutes ago

New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 3 hours ago

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 12 hours ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 12 hours ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 15 hours ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031

View all EQS

Published on 09/11/2026 at 07:00, 2 days 3 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 2 days 3 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 2 days 15 hours ago

Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 07:00, 3 days 3 hours ago

2026 H1 results and new identity
Published on 09/09/2026 at 18:45, 3 days 16 hours ago

Successful launch of a €500 million bond issue

View all LES ECHOS COMFI WIRE

News